Pneumococcal vaccine: uptake remains low among elderly

Access to the full content of this site is available only to registered healthcare professionals. Register to read more


  • Despite data demonstrating the efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) in conjunction with a 23-valent pneumococcal polysaccharide vaccine (PPSV23) series in adults ≥65 y, uptake and related Medicare claims have been persistently low.

Why this matters